Anti-convulsant efficacy of long-acting injectable cannabidiol formulation (IVL5005) in the pentylenetetrazol-induced convulsions, with pharmacokinetic characterization
These results indicate that IVL5005 may overcome key limitations of oral CBD and support its further development as a long-acting therapeutic option for epilepsy.
Authors
- Slgirim Lee
- Hyun‐Je Park (ORCID: https://orcid.org/0009-0008-3632-947X)
- Young Dai Seo
- Joo Young (ORCID: https://orcid.org/0000-0002-4684-7181)
- Woo‐Chan Son (ORCID: https://orcid.org/0000-0002-4052-8745)
- So‐Young Youm
- Kun Hee Park
- Jae Ho Kim (ORCID: https://orcid.org/0000-0003-4323-4790)
- Aeri Song (ORCID: https://orcid.org/0000-0003-4541-3004)
Institutions
- Ulsan College (KR)
- Yuhan University (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Korea Telecom (South Korea) (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fphar.2025.1692123
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00